Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer

Mariia Kiriukova, Daniel de la Iglesia Garcia, Nikola Panic, Maryana Bozhychko, Bartu Avci, Patrick Maisonneuve, Enrique de-Madaria, Gabriele Capurso, Vasile Sandru, Mariia Kiriukova, Daniel de la Iglesia Garcia, Nikola Panic, Maryana Bozhychko, Bartu Avci, Patrick Maisonneuve, Enrique de-Madaria, Gabriele Capurso, Vasile Sandru

Abstract

Background: Malnutrition and cachexia are common in patients with advanced pancreatic ductal adenocarcinoma (PDAC) and have a significant influence on the tolerance and response to treatments. If timely identified, malnourished PDAC patients could be treated to increase their capacity to complete the planned treatments and, therefore, possibly, improve their efficacy. Aims: The aim of this study is to assess the impact of nutritional status, pancreatic exocrine insufficiency (PEI), and other clinical factors on patient outcomes in patients with advanced PDAC. Methods: PAncreatic Cancer MAlnutrition and Pancreatic Exocrine INsufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer (PAC-MAIN) is an international multicenter prospective observational cohort study. The nutritional status will be determined by means of Mini-Nutritional Assessment score and laboratory blood tests. PEI will be defined by reduced fecal elastase levels.

Main outcome: adherence to planned chemotherapy in the first 12 weeks following the diagnosis, according to patients' baseline nutritional status and quantified and reported as "percent of standard chemotherapy dose delivered."

Secondary outcomes: rate of chemotherapy-related toxicity, progression-free survival, survival at 6 months, overall survival, quality of life, and the number of hospitalizations.

Analysis: chemotherapy dosing over the first 12 weeks of therapy (i.e., percent of chemotherapy received in the first 12 weeks, as defined above) will be compared between well-nourished and malnourished patients.

Sample size: based on an expected percentage of chemotherapy delivered of 70% in well-nourished patients, with a type I error of 0.05 and a type II error of 0.20, a sample size of 93 patients per group will be required in case of a percentage difference of chemotherapy delivered of 20% between well-nourished and malnourished patients, 163 patients per group in case of a difference of 15% between the groups, and 356 patients per group in case of a 10% difference. Centers from Russia, Romania, Turkey, Spain, Serbia, and Italy will participate in the study upon Local Ethics Committee approval. Discussion: PAC-MAIN will provide insights into the role of malnutrition and PEI in the outcomes of PDAC. The study protocol was registered at clinicaltrials.gov as NCT04112836.

Keywords: chemotherapy; dose-intensity; exocrine pancreatic insufficiency; locally advanced; metastatic; nutritional status; pancreatic cancer.

Copyright © 2020 Kiriukova, de la Iglesia Garcia, Panic, Bozhychko, Avci, Maisonneuve, de-Madaria, Capurso and Sandru.

References

    1. Cancer IIAfRo Globocan (2018). Available online at: (accessed November 4, 2018).
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. (2016) 66:7–30. 10.3322/caac.21332
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. (2020) 70:7–30. 10.3322/caac.21590
    1. DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. (1999) 10 (Suppl. 4):140–2. 10.1093/annonc/10.suppl_4.S140
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. (2011) 12:489–95. 10.1016/S1470-2045(10)70218-7
    1. Loumaye A, Thissen JP. Biomarkers of cancer cachexia. Clin Biochem. (2017) 50:1281–8. 10.1016/j.clinbiochem.2017.07.011
    1. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. (2013) 10:90–9. 10.1038/nrclinonc.2012.209
    1. Danai LV, Babic A, Rosenthal MH, Muir A, Lien EC, Mayers JR, et al. . Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. (2018) 558:600–4. 10.1038/s41586-018-0235-7
    1. Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, et al. . Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology. (2015) 15:19–24. 10.1016/j.pan.2014.11.006
    1. Partelli S, Frulloni L, Minniti C, Bassi C, Barugola G, D'Onofrio M, et al. . Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Dig Liver Dis. (2012) 44:945–51. 10.1016/j.dld.2012.05.017
    1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. (2011) 378:607–20. 10.1016/S0140-6736(10)62307-0
    1. Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep. (2013) 15:182–9. 10.1007/s11912-012-0290-4
    1. Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, Gajdos C, et al. . Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine. (2014) 93:e198. 10.1097/MD.0000000000000198
    1. Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, et al. . Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. (2013) 108:236–41. 10.1002/jso.23392
    1. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med. (2011) 364:1817–25. 10.1056/NEJMoa1011923
    1. Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, et al. . Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. (2018) 19:97–104. 10.1016/j.pan.2018.10.003
    1. Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante J, Moore M, et al. . Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. New Engl J Med. (2013) 369:1691–703. 10.1056/NEJMoa1304369
    1. Scheithauer W, Putora P M, Grünberger B, Eisterer W, Wöll E, Prager G, et al. . Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Ther Adv Gastroenterol. (2019) 12:1–8. 10.1177/1756284819877635
    1. Gasslander T, Holmberg B, Permert J. Pancreas 2000 - a new concept for education and development in pancreatology. Pancreatology. (2005) 5:545–46. 10.1159/000087495
    1. Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, et al. . 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer. (2017) 79:41–9. 10.1016/j.ejca.2017.03.022
    1. Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, et al. . Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget. (2017) 8:79884–96. 10.18632/oncotarget.20168
    1. Fitzsimmons D, Johnson C D, George S, Payne S, Sandberg AA, Bassi C, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC study group on quality of life. Eur J Cancer. (1999) 35:939–41. 10.1016/S0959-8049(99)00047-7
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. . New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. (2009) 45:228–47 10.1016/j.ejca.2008.10.026
    1. Barret M, Malka D, Aparicio T, Dalban C, Locher C, Sabate JM, et al. . Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. Oncology. (2011) 81:395–402. 10.1159/000335478
    1. Klute K, Brouwer J, Jhawer M, Sachs H, Gangadin A, Ocean A, et al. . Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: a multicentre analysis. Eur J Cancer. (2016) 63:189e200. 10.1016/j.ejca.2016.05.011

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever